These results indicate that patients with DM accompanied by RP-ILD had an very high mortality rate within the first year after disease diagnosis and that patients with anti-MDA5 antibodies and/or those belonging to the CADM group require urgent attention with respect to the development of RP-ILD. Here, IFIH1 is linked to clinically amyopathic dermatomyositis.